Updated: 12 June 2013
NEW----Link to online session planner

Programme Overview

Wednesday 12 June 2013
17:00-18:00  ECFS Annual General Meeting 
18:30-20:00  Opening Plenary 
20:00-21:30  Welcome Reception 
Thursday 13 June 2013
07:15-08:15  Round Tables 
07:00-08:15 Johns Hopkins University School of Medicine Satellite Symposium  - click for Programme
08:30-10:00  Symposium 1 - CFTR modulators 
Moderators: I. Fajac (FR) / T. Lee (UK)
  Correcting and Potentiating CFTR - Michael Boyle (US) 
  ENaC blockers - Henry Danahay (UK)
  New Correctors and Potentiators from high throughput Screening - Luis Galietta (IT) 
  CF drug discovery and personalized medicine - Fred Van Goor (US) 
08:30-10:00  Symposium 2 - Upper Airways Infection
Moderators: S. Molin (DK) / L. Dupont (BE)
  Upper and lower respiratory tract microbiome in CF and non CF - Michael Cox (UK)
  Host response to sinus infection -AT Peters (US)
  Medical interventions for sinus infection in CF - Kasper Aanaes (DK)
  Importance of sinus disease in patients undergoing lung transplantation - C. Knoop (BE)
08:30-10:00  Symposium 3 - Newborn Screening
Moderators:  L. Vilarinho (PT) / P. Farrell (US)
  Neonatal screening in Europe: common goals, many protocols!  - Kevin Southern (UK)
  Incorporating DNA analysis into neonatal screening protocols: Pluses and minuses - Philip Farrell (US)/Richard Parad (US)
  The arguments for and against a safety net strategy in the NBS protocol - Olaf Sommerburg (DE)

Newborn screening in Australia, investigating alternative strategies such as PAP - Enzo Ranieri (AU)

08:30-10:00    Symposium 4 - Beyond Epidemiology: Expanding the Role of CF Registries
Moderators: E. McKone (IE) / L . Pereira (PT)
  Registry meets Regulators: Using registries for Pharmacovigilence - Irmgard Eichler (EU)
  Nature v. Nurture: Interpreting differences in outcomes in and across EU countries - Ed McKone (IE)
  Standardising CT Scans - Harm Tiddens (NL)
  Registry meets Politics: EuroCareCF 2007-2013 - Anil Mehta (UK)
08:30-10:00     Symposium 5 - Coping and resilience
Moderators: J. Abbott (UK) / G. Latchford (UK) 
  An overview of coping and resilience in CF - Janice Abbott (UK) 
  Illness representations, chronic illness and coping - John Weinman (UK) 
  Illness representations and quality of life in CF - Gregory Sawicki (US) 
  Illness representations, coping and adherence - Rob Horne (UK) 
08:30-10:00      Symposium 6 - Outcome Determinants in CF
Moderators: M. Schechter (US) / M. do Céu Machado (PT)
  Socioeconomic - Michael Schechter (US) 
  Sex - Nicholas Simmonds (UK) 
  Climate/Environment - JM. Collaco (US) 
  Adherence - Alexandra Quittner (US) 
10:00-10:30  Coffee Break 
10:30-12:00 Symposium 7 - The organisation of the CF Unit
Moderators: M. Boyle (US) / H. Heijerman (NL)
  Starting from Scratch: Building a New CF Unit - Charles Gallagher (IE)
  Managing the rapid growth of the centre - Andrew Jones (UK) 
  Training and motivating CF teams - Isabelle Sermet (FR)
  Quality Control: the role of peer review - Michael Boyle (US) 
10:30-12:00  Symposium 8 - Translating what we have learned from Bacterial Genomics to CF Care
Moderators: J. Foweraker (UK) / I. Sá Correia (PT)
  Introduction to the technology - what we can learn from the next generation  - Eshwar Mahenthiralingam (UK) 
  Pseudomonas aeruginosa - Lutz Wiehlmann (DE) 
  Staphylococcus aureus - Barbara Kahl (DE) 
  Achromobacter and other gram negatives - John Lipuma (US)  
10:30-12:00   Symposium 9 - What to do with a positive screening for metabolic complications?
Moderators: A. Munck (FR) / A.M. Boot (NL) 
  Glucose intolerance: When to start insulin  - David Zangen (IL) 
  Delayed puberty; is it still a problem? Should we screen and treat- Marie Bournez (FR) 
  Effectiveness of nutritional interventions: What conclusions from the literature? Roderick Houwen  (NL)
  Bone mineral density and Vitamin D status in adolescents – what needs to be done?  - A.M. Boot (NL) 
10:30-12:00      Symposium 10 - Learning more about CFTR
Moderators: M. Amaral (PT) / L. Galietta (IT)
  How does deltaF508 CFTR travel to the cell surface? - Carlos Farinha (PT)
  Opportunities for pharmacological modulation of CFTR at the cell surface - David Sheppard (UK)
  Novel opportunities for drug development using primary CF organoids - Florijn Dekkers (NL)
  Functional interaction of CFTR with SLC26 anion transporters and anoctamins - Karl Kunzelmann (DE)
10:30-12:00       Symposium 11 - Airway Clearance Challenges in Reactive Airways Disease
Moderators: I. Maguire (IE) / L. Lannefors (DK) 
  Pathophysiology and medical management of Reactive Airways Disease in CF - Eitan Kerem (IL) 
  Preparing the airways for Airway Clearance: optimising inhalation therapy - Brenda Button (AU) 
  Do's and Dont's of Airway Clearance in reactive airways disease - Maggie McIlwaine (CA)  
  Exercise and reactive airways disease - Mark Elkins (AU) 
10:30-12:00 Symposium 12 - Innate Immunity: Is it important in the CF Lung? 
Moderators: D. Hartl (DE) / A. Gaggar (US)
  Pathogen-recognition in CF airways - Catherine Greene (IE)
  Proteolytic cleavage of SP-D in CF Lung Disease - A. Gaggar (US)
  Biometals in CF inflammation - David Reid (AU) 
  Assessing early inflammation based on biomarkers – the AREST study - Peter Sly (AU) 
12:00-15:00  Lunch 
12:30-14:00  Gilead Satellite Symposium - click for Programme
12:30-14:00  Pharmaxis Satellite Symposium - click for Programme
14:00-15:00  EPoster Sessions:
Nursing/Psychosocial Issues | Lung Disease
Guided Poster Tours:
Screening/Diagnosis |Microbiology |Gastrointestinal/Liver Disease/Metabolic complications/Nutrition
15:00-16:30   Workshop 1 - Infection in the clinic
Moderators: H. Krogh Johansen (DK) / K. Van der Ent (NL)
  Abstract WS1.1: Evolutionary pathways in two dominant clinical Pseudomonas aeruginosa clones - Helle Krogh Johansen (DK) 
  Abstract WS1.2: Three clinically distinct chronic pediatric airway infections share a common core microbiota - Lucas Hoffman (US)
  Abstract WS1.3: Respiratory microbiota dynamics in newborns with cystic fibrosis and healthy controls: a longitudinal study - Sabine Prevaes (NL) 
  Abstract WS1.4: Significant bacterial infection missed using cough swabs compared to bronchoalveolar lavage in 1-year old newborn screened CF infants - Lena Thia (UK) 
  Abstract WS1.5: First evidence of Mycobacterium abscessus biofilm in the lungs of chronically infected CF patients - Tavs Qvist (DK)
  Abstract WS1.6: Successful Treatment of Mycobacterium abscessus Infection in Cystic Fibrosis Patients using a Novel Regimen - Andrew Jones (UK)
15:00-16:30   Workshop 2 - The experience of parents
Moderators: J. Noordhoek (NL) / M. Jessup (AU)
  Introduction by Teresa Oliveira (PT) and Hélio Ferreira (PT)
  Abstract WS2.1: “Feeling my way”: Information needs for parents whose child has been diagnosed with CF following newborn screening - Melanie Jessup (AU)
  Abstract WS2.2: What do parents experience and how do they cope with the AREST-CF Early Surveillance Program for infants and children with cystic fibrosis? - Cindy Branch-Smith (AU)
  Abstract WS2.3: Parents’ roles and involvement in young adults’ clinic appointments - Lucy Stuttard (UK) 
  Abstract WS2.4: Use of non-prescribed medicines, supplements and therapies by children with cystic fibrosis, other chronic illnesses and children with an acute injury - A comparative mixed-methods study - Matthew Hurley (UK)
  Abstract WS2.5: The development, implementation and evaluation of a therapeutic group for non-affected siblings of children and young people with Cystic Fibrosis attending a Regional Paediatric CF centre - Clare Dixon (UK) 
15:00-16:30    Workshop 3 - What's up in the gut
Moderators: B. Plant (IE) / A. Isabel Lopes (PT)
  Abstract WS3.1: Gastric aspiration into the CF lung; relationship with reflux symptoms and lung function - Gemma Crossfield (UK) 
  Abstract WS3.2: Higher levels of fecal calprotectin levels are associated with SIBO in cystic fibrosis after lung transplantation - Emina Halilbasic (AT)
  Abstract WS3.3: Molecular characterization of fecal microbiota and metabolic profiles association in cystic fibrosis patients - Valerio Iebba (IT)
  Abstract WS3.4: Clostridium difficile, but not Giardia lambliais, is a frequent finding in the stool of CF patients - Lutz Naehrlich (DE) 
  Abstract WS3.5: Clostridium difficilie in adult cystic fibrosis (CF): prevalence, ribotyping and toxigenic capability. A prospective study - Michael Harrison (IE) 
  Abstract WS3.6: Probiotic intake improves the gastrointestinal health of cystic fibrosis patients - Ana de Blas Zapata (ES) 
15:00-16:30  Workshop 4 - New Insights in CFTR biology
Moderators: D. Sheppard (UK) / A. Grangeia (PT)
  Abstract WS4.1: New molecular models of CFTR based on ABC transporter structures - Brice Hoffmann (FR) 
  Abstract WS4.2: Exploration of the ATP binding site in CFTR-NBD1 for enhanced ligand binding - Merav Fichman (IL)
  Abstract WS4.3: Rescue of F508del-CFTR without the regulatory insertion (?RI) and regulatory extension (?RE) in combination with genetic revertants and small molecules - Inna Uliyakina (PT)
  Abstract WS4.4: Restoration of F508?-CFTR trafficking and function by liposome-mediated delivery of antibodies against cytokeratin 8 - Benoît Chatin (FR)
  Abstract WS4.5: LMTK2 Regulates CFTR Endocytosis by Phosphorylation at CFTR SER-737 - Simao Luz (PT) 
  Abstract WS4.6: MicroRNA-30s negatively regulate Planar Cell Polarity genes in Human Cystic Fibrosis Bronchial Epithelial cells - Sabrina Noel (BE)
15:00-16:30   Workshop 5 - Inflammatory Connections
Moderators: D. Hartl (DE) / L. Touqui (FR)
  Abstract WS5.1: High degree of variation in virulence of clonal Burkholderia cenocepacia ST32 isolates from cystic fibrosis patients in zebra fish embryos - Klara Dedeckova (CZ)
  Abstract WS5.2: Toll-like receptor 9 deficiency protects mice against Pseudomonas aeruginosa pulmonary infection - Fatima Ben Mohamed (FR)
  Abstract WS5.3: GSNOR Inhibitors as Potential, Novel Anti-inflammatory Therapy in Cystic Fibrosis - Steven Shoemaker (US)
  Abstract WS5.4: Increased production of IL-17A in circulating Th17 and dysfunctional Tregs in adults with cystic fibrosis-related diabetes - Sophie Ziai (CA)
  Abstract WS5.5: Impact of Antibiotic Treatment on Concentration of Pro-inflammatory Cytokines in Nasal Lavages of CF Patients - Julia Hentschel (DE)
  Abstract WS5.6: Regulatory T cells in cystic fibrosis patients infected with Pseudomonas aeruginosa - A. Hector (DE)
15:00-16:30    Workshop 6 - Delivering and monitoring care
Moderators: S. Madge (UK) / K. De Rijcke (BE)
  Abstract WS6.1: A cross-sectional evaluation of factors influencing adherence in children with cystic fibrosis - Nicola Goodfellow (UK)
  Abstract WS6.2: The Impact of Transition to Adult Services on Weight and BMI for Patients with Cystic Fibrosis - Caroline Cousins (UK) 
  Abstract WS6.3: Airway clearance and physical activity - Results from a UK Survey - Kate Ferguson (UK)
  Abstract WS6.4: Benchmarking in Germany: an expanding systematic quality improvement project - Nadja Niemann (DE) 
  Abstract WS6.5: Experience and satisfaction of patients and parents with CF services – a nationwide survey in Germany - Gratiana Steinkamp (DE)
  Abstract WS6.6: A prospective multi centre study to examine the impact of home intravenous antibiotic treatment (H-IVAT) on carer well being - Holly Hope (UK)
  Abstract WS6.7: Patient responses to the introduction of telemedicine and EHRs - John Wilson (AU) 
  Abstract WS6.8: Intensive Care Unit Outcomes in Cystic Fibrosis Patients Admitted with Hemoptysis vs All Other Indications - Boaz Markewitz (US) 
  Abstract WS6.9: Urinary Kidney Injury Molecule – 1 is superior to creatinine and cystatin-C based formulas at predicting chronic kidney disease in patients with cystic fibrosis - Andrew Prayle (UK) 
16:30-17:00  Coffee Break 
17:00-18:30  Workshop 7 - Novel Therapies
Moderators: E. Kerem (IL) / I. Fajac (FR)
  Abstract WS7.1: Multi-target corrective effect of vardenafil on F508del-CFTR function and localization - Barbara Dhooghe (BE) 
  Abstract WS7.2: Ex vivo effect of CFTR modulators VX770, VX809 and PTC124 on CFTR-mediated chloride secretion in rectal biopsies from CF patients - Sheila Scheinert (DE)
  Abstract WS7.3: VX-661, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation: interim analysis - Scott Donaldson (US)
  Abstract WS7.4: Lumacaftor, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in CF patients with the F508Del-CFTR mutation: Phase 2 interim analysis - Michael Boyle (US)
  Abstract WS7.5: Interim results of the Phase 3 open-label study of ataluren in nonsense mutation cystic fibrosis (nmCF) - Eitan Kerem (IL) 
  Abstract WS7.6: UK and Ireland review of Ivacaftor in severe CF: impact on lung function and weight - Peter Barry (UK)
17:00-18:30   Workshop 8 - Microbial Communities: relationships and disease
Moderators: E. Mahenthiralingham (UK) / B. Kahl (DE)
  Abstract WS8.1: The role of second-generation sequencing in describing the fungal microbiota in the adult cystic fibrosis (CF) airway and its correlation with clinical phenotype - Michael Harrison (IE)
  Abstract WS8.2: Effect of Staphylococcus aureus on the outcome of pulmonary Pseudomonas aeruginosa infection in a murine model - Avril Monahan (UK)
  Abstract WS8.3: Cystic fibrosis transmembrane conductance regulator (CFTR) allelic variants relate to shifts in fecal microbiota of cystic fibrosis patients - Valerio Iebba (IT)
  Abstract WS8.4: Temporal bacterial community dynamics of cystic fibrosis lung infections - Leah Cuthbertson (UK)
  Abstract WS8.5: Airway bacterial community structure and correlation during health and disease - Gisli Einarsson (UK) 
  Abstract WS8.6: Interaction of microorganisms modulating the Cystic Fibrosis clinical severity - Fernando de Lima Marson (BR) 
17:00-18:30    Workshop 9 - Clearing the airways
Moderators: M. McIlwaine (CA) / M. Donadio (BR)
  Abstract WS9.1: Effectiveness of airway clearance techniques when patients chose their airway clearance technique - Maggie McIlwaine (CA) 
  Abstract WS9.2: Patient and physiotherapist reported adherence to airway clearance therapy, inhalational therapy and exercise in cystic fibrosis - Brenda Button (AU)
  Abstract WS9.3: Bronchial hyperreactivity related to 4 commonly used inhalation drugs in cystic fibrosis - Hanneke Eyns (BE)
  Abstract WS9.4: Non invasive ventilation as airway clearance technique compared to PEP in adult patients with cystic fibrosis - Maria Cecilia Rodriguez (SE)
  Abstract WS9.5: Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial – A randomised, controlled trial comparing 0.9% v 3% v 6% nebulised saline - Mark Elkins (AU) 
  Abstract WS9.6: Cystic fibrosis-related postural and baropodometric changes: a comparison with healthy individuals - Marcio Donadio (BR)
17:00-18:30     Workshop 10 - Screening, Genetics & Biomarkers
Moderators: H. Cuppens (BE) / C. Bombieri (IT)
  Abstract WS10.1: The performance of the UK national newborn screening (NBS) programme for CF; results from a UK Regional Paediatric Network - Julia Harrington (UK)
  Abstract WS10.2: Complete sequencing of 2,000 cystic fibrosis and CFTR-Related Disease high risk alleles - Joanna Brock (UK)
  Abstract WS10.3: What can next-generation sequencing do for CF? - Jessica Varilh (FR)
  Abstract WS10.4: A New Molecular Strategy using CFTR2 Data for Improving IRT/DNA Screening - Philip Farrell (US)
  Abstract WS10.5: Impact of CFTR mutations affecting mRNA processing and looking for therapeutic compounds - Anabela Ramalho (PT)
  Abstract WS10.6: Organ-specific CFTR dysfunction: comparison of biomarkers for CF diagnosis and CFTR modulator effects - Lea Pinders (DE) 
17:00-18:30      Workshop 11 - Adult Care - Partnership with care teams
Moderators: N. Simmonds (UK) / D. Hubert (FR)
  Abstract WS11.1: Characterising extreme survival in cystic fibrosis: a case series of over-50 year olds - Panayiotis Constantinou (UK)
  Abstract WS11.2: Change pathways: The power of engaging in partnerships to change and enhance care for adults with cystic fibrosis - Hugh Greville (AU)
  Abstract WS11.3: Improving communication between adults with cystic fibrosis and their CF physician - Dominique Hubert (FR)
  Abstract WS11.4: Education and employment: a qualitative exploration of the beliefs, aspirations and experiences of young people with CF - Gary Latchford (UK)
  Abstract WS11.5: The effect of social deprivation, disease severity, and time in hospital on employment chances in the UK cystic fibrosis population: A longitudinal study - David Taylor-Robinson (UK)
  Abstract WS11.6: Unmet needs in end of life care for the adult cystic fibrosis patient: a review of expectations, challenges, and current practice - Bridget Quinn (US)
17:00-18:30       Workshop 12 - Assessment of disease severity
Moderators: D. VanDevanter (US) / T. Pressler (DK)
  Abstract WS12.1: Evidence of Diminished FEV1 in CF 6-year-olds followed in the European CF Registry, 2007 – 2009 - Donald VanDevanter (US)
  Abstract WS12.2: The impact of switching to the new Global Lung Function Initiative equations on spirometry results in the UK CF Registry - Paul Aurora (UK)
  Abstract WS12.3: Prognostic value of the 6 minute walk test in adults with cystic fibrosis - Pierre-Régis Burgel (FR)
  Abstract WS12.4: Determinants of 6 minute walking distance and desaturation during the 6 minute walk test in adults with cystic fibrosis - Pierre-Régis Burgel (FR)
  Abstract WS12.5: Lung clearance index and exercise capacity among children with mild CF- and non-CF bronchiectasis - Elpida Hatziagorou (GR)
  Abstract WS12.6: Comparison of two methods to identify bronchiectasis on chest computed tomography scans in two cohorts of young patients with cystic fibrosis - Wieying Kuo (NL)
  Pulmonary emphysema in cystic fibrosis detected by densitometry on chest multidetector computed tomography (MDCT) - Mark Wielpütz (DE)
19:00-20:30  Vertex Satellite Symposium - click for Programme
Friday 14 June 2013
07:15-08:15  Round Tables 
07:15-08:15 Abbott Satellite Symposium - click for Programme
08:30-10:00  Symposium 13 - New Inhaled Therapies
Moderators: C. Barreto (PT) / K. Van der Ent (NL)
  Inhaled antibiotics – P. Flume (US)
  Anticholinergics – Felix Ratjen (CA)
  Inhaled nitric oxide – Christopher Miller (CA)
  Delivering drugs to the airways: DPI or nebulizer? – D. Geller (US)
08:30-10:00    Symposium 14 - Fungi in CF
Moderators: R. Moss (US) / G. McElvaney (IE)
  Fungal detection in the real world? - Jean-Philippe Bouchara (FR)
  Metagenome: fungal and bacterial interactions - Laurence Delhaes (FR) 
  Aspergillus in CF - what can we learn from other lung diseases? - Richard Moss (US)
  To treat or not to treat? - Shawn Aaron (CA)
08:30-10:00     Symposium 15 - Planning your Research – The next Steps
Moderators: R. Dentice (AU) / A. Morton (UK)
  Turning ideas into specific aims - Mark Elkins (AU)
  Tips for writing a successful grant application - Alexandra Quittner (US)
  Formulating a budget - Judy Bradley (UK)
  How a grant review panel works -  Susan Madge (UK)
08:30-10:00 Symposium 16 - Ion transport regulation in normal and CF organ physiology
Moderators: K. Kunzelmann (DE) / H. De Jonge (NL)
  Primary Ion transport defects in the CF lung - Marcus Mall (DE) 
  Role of anion transport in the intestine - Lane Clarke (US) 
  New insights into the role of bicarbonate secretion in the pancreas - Michael Gray (UK)
  Luminal pH regulation and epithelial barrier function - Ursula Seidler (DE) 
08:30-10:00      Symposium 17 - News from the PERT front?!
Moderators: G. Connett (UK) / D. Borowitz (US)
  Sense and non-sense in PERT practice -Frank Bodewes (NL)
  Pancreatic function in the first year of life - Brian O'Sullivan (US)
  Effects of CFTR potentiators on the gastrointestinal tract - Drucy Borowitz (US)
  Can we maintain/restore pancreatic sufficiency: lessons from other diseases (Swachman) - Peter Durie (CA)
08:30-10:00       Symposium 18 - Grand Rounds in Pulmonary Disease
Expert Panel: K. De Boeck (BE) / H. Heijerman (NL) / A. Smyth (UK) / E. McKone (IE) / C. Barbara (PT)
  Severe persistent arthritis ceased after discontinuation of omalizumab therapy used for treatment of allergic bronchopulmonary aspergillosis (ABPA) - Cordula Koerner (DE)
  Toxic megacolon as fatal complication of antibiotic treatment in cystic fibrosis. Possibilities of ECMO treatment - Ferenc Karpati (SE)
  It's a family affair -a diagnostic dilemma in a family with cystic fibrosis - Imogen Rose (UK)
  A case of accelerated clinical decline in association with Exophiala dermatitidis colonisation in cystic fibrosis - Imogen Felton (UK)
  First description of arxula adeninivorans causing an invasive pulmonary mycosis and sepsis in a 34-year-old patient with cystic fibrosis - Jobst Röhmel (DE)
  Man´s best friend? - William Flight (UK) 
10:00-10:30  Coffee Break 
10:30-12:00 Symposium 19 - Cost of  CF Care
Moderators C. Goss (US) / S. Elborn (UK)
  Funding of CF Care around the World - Christopher Goss (US)
  Pharmacoecomonics of new therapies - Kees van Gool (AU)
  Personalised medicine in CF is unaffordable
Pro: Ian Balfour-Lynn (UK)
Con: Kris De Boeck (BE)
10:30-12:00    Symposium 20 - The pulmonary and intestinal microbiome in CF
Moderators: J. Leitao (PT) / J. Lipuma (US)
  Interactions between organisms in the microbiome of the lung -  Jean Marc Rolain (FR)
  The gut microbiome in CF - R. DeLisle (US)
  Direct sampling of CF lungs indicates that DNA-based analyses  of upper airway specimens can misrepresent lung microbiota - Pradeep Singh (US)
  Impact of intestinal microbiome in the development of the CF respiratory microbiome in infants - Devin Koestler (US)
10:30-12:00     Symposium 21 - Genetics and Diagnosis
Moderators: J. Lavinha (PT) / G. Cutting (US)
  Update on CF modifiers - Harriet Corvol (FR) 
  Role of next generation sequencing in CF - Harry Cuppens (BE) 
  Diagnosis of CF and related disorders in the newborn infant - Carlo Castellani (IT) 
  Diagnosis of CF and related disorders in the older child and adult - Cristina Bombieri (IT) 
10:30-12:00     Symposium 22 - Altered host defense function in CF
Moderators: M. Chanson (CH) / L. Clarke (PT) 
  Remodelling in CF - Bob Scholte (NL) 
  Further lessons from the CF pig - Paul McCray (US) 
  Altered epithelial host cell function - Clifford Taggart (UK) 
  Altered immune cell function - Emer Reeves (IE) 
10:30-12:00     Symposium 23 - CF in the shadow of co-morbidities
Moderators: T. Goldschmidt (PT) / M. Bryon (UK)
  Child developmental and behavioural co-morbidities - Mandy Bryon (UK)
  CF related diabetes - Sylvia Ockhorst (NL)
  Pain in CF: assessment and self-management - Trudy Havermans (BE)
  Physical co-morbidities of CF - Lena Hjelte (SE)
10:30-12:00      Symposium 24 - Investigator-led trials
Moderators: G. Rault (FR) / S. Gartner (ES)
  European MRSA eradication protocol: Feasibility - Damian Downey (UK)
  Oestrogens and Pseudomonas: how to translate into a clinical trial- the OCP - Gerry McElvaney (IE)
  Physiotherapy: studying it is impossible? - Maggie McIlwaine (CA)
  Outome measures in preschool children and infants - Paul Aurora (UK)
12:00-15:00  Lunch 
12:30-14:00  Novartis Satellite Symposium  - click for Programme
14:00-15:00 ePoster Sessions:
CFTR/Genetics | Microbiology
Guided Poster Tours
Immunology/Pulmonology | Physiotherapy | Delivery of Care/Epidemiology
15:00-16:30 Special Symposium - ECFS/CFF Guidelines for the Management of Non Tuberculous Mycobacteria in CF
Moderators: C. Haworth (UK) / B. Marshall (US) 
  The microbiology of nontuberculous mycobacteria - Jean Louis Herrmann (FR) 
  Epidemiology and risk factors for NTM – Andres Floto (UK)  
  Diagnosing NTM in CF – Charles Haworth (UK) 
  Treatment of Mycobacterium  – Ken Olivier (US) 

Workshop 13 - Imaging and physiology for assessment of infection
Moderators: H. Tiddens (NL) / L. Guedes Vaz (PT)

  Abstract WS13.1: Lung clearance index predicts time to pulmonary exacerbation in children with CF - Francois Vermeulen (BE) 
  Abstract WS13.2: Lung Clearance Index (LCI) and airway infection in CF - Katherine O'Neill (UK)
  Abstract WS13.3: Lung Clearance Index: a tool to assess the response to intravenous treatment among children with Cystic Fibrosis - Elpida Hatziagorou (GR) 
  Abstract WS13.4: Chest HRCT ( cCT) score predicts later Pseudomonas infection in young children with cystic fibrosis - Sonia Volpi (IT)
  Abstract WS13.5: Structural correlation of multiple breath washout indices derived from alveolar slope analysis in adult cystic fibrosis - Katharine Hurt (UK) 
  Abstract WS13.6: Evidence of short-term acinar response following intravenous antibiotics therapy in adults with Cystic Fibrosis - Eef Vanderhelst (BE) 
15:00-16:30  Workshop 14 - Exercise for Everyone
Moderators: B. Arets (NL) / B. O'Neill (UK)
  Abstract WS14.1: Evaluation of physical activity using the Habitual Activity Estimation Scale (HAES) questionnaire in a multicenter study - Nancy Alarie (CA)
  Abstract WS14.2: Assessing components of fitness in cystic fibrosis: The practicality and value of using a battery of exercise tests in CF clinical practice - Adrian Morris (UK)
  Abstract WS14.3: Chronic inflammation and infection affect exercise training response in adolescents with cystic fibrosis - Hubertus Arets (NL)
  Abstract WS14.4: Effects of individualised aerobic exercise training in adults with cystc fibrosis: A 4 year controlled trial - Milos Petrovic (AT)
  Abstract WS14.5: Interval Exercise Training in Cystic Fibrosis – Effects on Maximal and Submaximal Exercise Capacity in Severely Affected Adults - Wolfgang Gruber (DE) 
  Abstract WS14.6: Physical activity, energy expenditure and quality of life in CF adults receiving intravenous antibiotics at home and in hospital - Heena Khiroya (UK)
15:00-16:30   Workshop 15 - Exploring & developing novel therapeutic strategies
Moderators: M. Mall (DE) / U. Seidler (DE)
  Abstract WS15.1: Development of a human model of airway epithelial cells invalidated for CFTR - Jessica Bellec (FR)
  Abstract WS15.2: Derivation of normal and cystic fibrosis human induced pluripotent stem cells (iPSCs) from airway epithelium - Roberto Loi (IT) 
  Abstract WS15.3: Human Amniotic Mesenchymal Stem Cells Modify the Function and Cytokine Production of F508del Airway Epithelial Cells Upon Coculture - Massimo Conese (IT) 
  Abstract WS15.4: Purinergic signalling regulates pancreatic epithelial transport and pancreatic stellate cells - Ivana Novak (DK)
  Abstract WS15.5: Effect of treatment with oligosaccharide nanomedicine OligoG on the rheology of cystic fibrosis sputum - Manon Pritchard (UK) 
  Abstract WS15.6: Development of nanomedicines for the treatment of pulmonary biofilm infections: insights from advanced fluorescence microscopy studies - Katrien Forier (BE) 
15:00-16:30    Workshop 16 - Nutrition matters
Moderators: S. Bell (AU) / A. Munck (FR)
  Abstract WS16.1: Treatment of early diagnosed CFRD with oral drugs versus insulin: An open prospective randomized study - Manfred Ballmann (DE)
  Abstract WS16.2: Glucose handling in CF – Implications for the diagnosis and screening of CFRD - Dilip Nazareth (UK)
  Abstract WS16.3: Vitamin D Supplementation in Patients with Cystic Fibrosis: A Pilot Randomized Controlled Trial - Terezia Pincikova (SE)
  Abstract WS16.4: Treatment Algorithm for Vitamin D Deficiency- A Review A Year On - Sejal Pandya (UK) 
  Abstract WS16.5: Comparison of cystic fibrosis adolescents with normal and low bone mineral density - Monika Mielus (PL) 
  Abstract WS16.6: Newborn Screening and Early Life Weight Recovery are Associated with Better Adolescent Growth in Children with CF - HuiChuan Lai (US) 
  Abstract WS16.7: Growth, nutritional care and biological assessment in newborn screened CF infants - Anne Munck (FR)
  Abstract WS16.8: Validation of bioelectrical impedance for routine monitoring of nutritional status in Cystic Fibrosis patients - Perrine Dusser (FR)

Workshop 17 - Novel anti-microbial therapies
Moderators: N. Høiby (DK) / S. Elborn (UK)

  Abstract WS17.1: Biofilm disruption and potentiating antimicrobial effects of a novel alginate oligomer on Pseudomonas aeruginosa in a murine lung infection model - Wang Hengzhuang (DK)
  Abstract WS17.2: ALX-109 potentiates the effect of inhaled antibiotics at killing Pseudomonas aeruginosa biofilms on human airway cells - Sophie Moreau-Marquis (US)
  Abstract WS17.3: Allicin revisited: antimicrobial activity against the Burkholderia cepacia complex and interaction with a peroxidase target - Daynea Wallock (UK)
  Abstract WS17.4: Anti-Pseudomonal bacteriophage cocktail reduces inflammatory responses in the murine lung - Rishi Pabary (UK)
  Abstract WS17.5: Evaluation of antibiofilm activity of new homoserine lactones (HSL) analogs of Pseudomonas aeruginosa - Aurelie Furiga-Chusseau (FR)
  Abstract WS17.6: Phase 3 Trial of Inhaled Levofloxacin (Aeroquin ™, MP-376, APT-1026) vs. Tobramycin Inhalation Solution (TIS) in Intensively Treated CF Patients Over 6 Months - S. Elborn (UK)
16:30-17:00 Coffee Break 
17:00-18:30   Workshop 18 - The Pregnancy "Epidemic"
Moderators: Guy Thorpe-Beeston (UK) / Isabelle Durieu (FR)
  Overview - Damian Downey (UK)
  Abstract WS18.1: Evolution of pregnancies in the French CF Registry: 1992-2011 - Lydie Lemonnier (FR) 
  Abstract WS18.2: Impact of Pregnancy in Women with Cystic Fibrosis (CF) - A Retrospective Single Centre Study - Audrey Tierney (AU)
  Abstract WS18.3: Pregnancy outcomes in cystic fibrosis: a 10-year experience from a UK centre - Mary Renton (UK)
  Abstract WS18.4: Does the presence of diabetes affect lung function outcomes in a pregnant individual with Cystic Fibrosis? - Elyssa Williams (AU)

Abstract WS18.5: When women with CF become mothers: A qualitative study on psychosocial impact and adjustment - Sophie Cammidge (UK)

17:00-18:30    Workshop 19 - Clinical Perspectives
Moderators: C. Goss (US) / S. Bell (AU)
  Abstract WS19.1: Mediastinal lymphadenopathy: a prognostic tool in adult patients with cystic fibrosis - Marco Mantero (IT) 
  Abstract WS19.2: Sinus pathogens in children with cystic fibrosis: do they relate to lower respiratory tract pathogens and is eradication successful? - Paul Wilson (UK)
  Abstract WS19.3: The value of deep oropharyngeal suction specimens in identifying lower airway bacteria in young children with cystic fibrosis - Michael Doumit (AU)
  Abstract WS19.4: A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with Cystic Fibrosis - Ruth Dentice (AU)
  Abstract WS19.5: Characterization of fungal colonization phenotypes in pediatric cystic fibrosis lung disease - Ute Graepler-Mainka (DE)
  Abstract WS19.6: Changes in the weather and the respiratory health of adults with cystic fibrosis - William Flight (UK)
  Abstract WS19.7: Assessment of habitual physical activity in adults with Cystic Fibrosis - Daniela Savi (IT)
  Abstract WS19.8: Use of Palivizumab to prevent Respiratory Syncytial Virus (RSV) infection in Cystic Fibrosis. A 10 year retrospective review pre and post introduction of palivizumab prophylaxis in Northern Ireland - Helen Groves (UK)
  Abstract WS19.9: A Prospective Multicenter Study To Dissect Staphylococcus aureus-Colonization From Infection In Cystic Fibrosis Patients - Barbara Kahl (DE)
17:00-18:30     Workshop 20 - CFTR Gene Modifiers
Moderators: G. Cutting (US) / H. Corvol (FR)
  Abstract WS20.1: Role of transcription factors and microRNAs in CFTR gene expression - Jennifer Bonini (FR)
  Abstract WS20.2: Over-expression of miR-494 and miR-145 correlates with CFTR and SMAD3 down-regulation in Cystic Fibrosis patients - Francesca Megiorni (IT)
  Abstract WS20.3: Transcriptomics of native nasal epithelium expressing F508del-CFTR and intersecting data from comparable studies - Luka Clarke (PT)
  Abstract WS20.4: The rs1078761 polymorphism is associated with reduced SPLUNC1 expression and increased pulmonary disease severity in Cystic Fibrosis patients - Aabida Saferali (CA)
  Abstract WS20.5: Genetic interaction of NOS-1 and CFTR gene and its association with cystic fibrosis severity - Fernando de Lima Marson (BR)
  Abstract WS20.6: High throughput screening as a source for novel cystic fibrosis therapeutic targets - Hugo Botelho (PT)
17:00-18:30      Workshop 21 - CFTR Mutations: partners and significance
Moderators: M. Amaral (PT) / A. Hinzpeter (FR)
  Abstract WS21.1: Cystic Fibrosis incidence in Portugal - Paula Pacheco (PT)
  Abstract WS21.2: Non-invasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis by quantitative real time Mutant Enrichment with 3’-Modified Oligonucleotides (MEMO) PCR - Marie Claire Vincent (FR)
  Abstract WS21.3: Clinical variability in patients with cystic fibrosis and d1152h mutation - Alida Casale (IT)
  Abstract WS21.4: Clinical and morphological characteristics of sporadic genetically determined pancreatitis compared with idiopathic pancreatitis: Higher risk of pancreatic cancer in CFTR variants - Xavier Pepermans (BE)
  Abstract WS21.5: Evolution of CFTR exon 10 and duplications in primates - Véronique Ladevèze (FR)
  Abstract WS21.6: A novel 5’ alternative CFTR mRNA isoform may be a cause of CFTR dysfunction in a patient with nasal polyposis - Emmanuelle Girodon (FR)
  Abstract WS21.7: Identification and characterization of two novel mutations in conserved sequences tags (CSTs) of CFTR gene - Rossella Tomaiuolo (IT)
  Abstract WS21.8: Exchange proteins directly activated by cyclic AMP: novel CFTR interactors? - Joao Fernandes (PT)
  Abstract WS21.9: Screening for Novel F508del-CFTR Correctors Identified by Pharmacophore Modelling through automated microscopy and NBD1 Folding Assays - Ana Romao (PT)
17:00-18:30       Workshop 22 - Host-pathogen Interactions
Moderators:I. sa Correia (PT) / G. Döring (DE)
  Abstract WS22.1: Basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis (ABPA) in CF: interim results of a longitudinal cohort study - Richard Moss (US)
  Abstract WS22.2: P. aeruginosa-induced apoptosis in airway epithelial cells is mediated by gap junctional communication in a CFTR-dependent manner - Davide Losa (CH)
  Abstract WS22.3: Role of macrophage proteases in the killing of intracellular bacteria - Noemi Cifani (IT)
  Abstract WS22.4: Biofilm formation by cystic fibrosis-relevant Burkholderia cepacia complex (Bcc) bacteria allows them to evade neutrophil anti-microbial activities - Mark Murphy (IE)
  Abstract WS22.5: Effect of the Burkholderia cenocepacia exoproteome on CFTR protein expression in human Cystic Fibrosis lung epithelial cell models - Sara Canato (PT)
  Abstract WS22.6: The Pseudomonas aeruginosa Pangenome: Impact of Genomic Diversity on Bacterial Pathogenicity and Host Response in Airway Infections - Burkhard Tümmler (DE)
17:00-18:30 Workshop 23 - Psychosocial Issues/Nursing - Case Presentations
Moderators: M. Kirszenbaum (FR) / J. van der Hulst (NL) / M. Butler (UK)
  Long Term Hospitalization of a 28 Years Old Female Patient with Cystic Fibrosis Related Diabetes(CFRD) and Turkish Background, Waiting for Lung Transplantation- A Multidisciplinary Approach Is Needed for Problem Solving Issues - Francis Hollander (NL)
  The use of clinical hypnosis to manage port access in a 5 year old girl (success with porty and squiggle!) - Kate Blakeley (UK)
  Psychological Support for a Patient with Cystic Fibrosis Prior to Lung Transplantation - Catherine O'Leary (UK)
  Metrics that Matter: Making the Invisible Visible as Adherence Support Moves a Patient from a Dependence on Unscheduled Rescue to Planned Prevention - Charlotte Hinchliffe (UK) / Charlotte Rose (UK)
  Caring for an Ageing CF Population: When Drugs Turn Nasty - Jamie Duckers (UK)
  The Ethics of Treatment Refusal in a 16 Year Old with Cystic Fibrosis - Harriet Conniff (UK)
19:00-20:30  Pari Satellite Symposium  - Click for Programme
Saturday 15 June 2013
09:00-10:30 Symposium 25 - Innovative Therapeutic Strategies directed at the Basic Defect
Moderators: M. Hug (DE) / G. McElvaney (IE)
  Stem cell therapy for CF - Christina Mauritz (DE)
  UK Consortium multidose clinical trial: protocol and baseline data - Jane Davies (UK)
  Readthrough therapies: a common target for genetic disease with PTC? - Alexandre Hinzpeter (FR)
  Using rectal biopsies from CF patients to assess potentiation residual CFTR function  - Marcus Mall (DE)
09:00-10:30   Symposium 26 - Burkholderia cepacia complex: still a problem?
Moderators: N. Høiby (DK) / T. Kidd (AU)
  Bcc infection resistence and virulence – Miguel Valvano (UK)
  Genomic adaption to the CF lung  - Isabel sa Correia (PT)
  Bcc infection: what have we learned about infection control and therapy – John Govan (UK)
  B.multivorans – How should we treat? – Andrew Jones (UK)
09:00-10:30  Symposium 27 - Biomarkers of exacerbation and lung function decline
Moderators: M. Conese (IT) / M. Cámara (UK)
  Bacterial signal molecules as biomarkers in CF - Miguel Cámara (UK)
  Sputum biomarkers for the prediction of acute pulmonary exacerbation -  Theodore Liou (US) 
  Plasma biomarkers to determine severity of lung function in CF - André Cantin (CA) 
  Biomarkers of lung function decline in children with CF - Frank Accurso (US) 
09:00-10:30   Symposium 28 - CF Liver Disease: what have the animal models taught us so far?
Moderators: HJ Verkade (NL) / S. Freedman (US) 
  Liver – gut interaction in CF mice - Steve Freedman (US)  
  The HCO3 umbrella hypothesis in biliary diseases –involved in CF liver disease? – Ulrich Beuers (NL) 
  The importance of the gallbladder in CF bile salt homeostasis – Dominique Debray (FR)  
  The development of liver fibrosis: Present and future targets of intervention - Detlef Schuppan (US)

Symposium 29 - Comparison of Outcomes across the EU
Moderators: P. Azevedo (PT) / L. Viviani (IT)

  Does your patient in the registry really have CF? - Kris De Boeck (BE)
  Liver disease in CF registries - Anders Lindblad (SE)
  EU-wide comparison of longitudinal changes in lung function and nutritional measures - Hanne Olesen (DK)
  Using Registries for Comparative Outcomes Research - Chris Goss (US)

Symposium 30 - Nursing CF across the adult lifespan
Moderators: E. J. Hunstad (NO) / D. Bilton (UK)

  The young adult - Diana Bilton (UK)
  On being a father with CF - M. Oudeman (NL)
  Nursing after a transplant - Karen Denaux (BE)
  CF diagnosis in adulthood - Kristine Colpaert (BE)
11:00-12:30 Plenary 
Moderators: S. Elborn (UK)
  CFTR2. The importance of understanding genotype - Garry Cutting (US) 
  Delivering quality care in CF. New challenges and new solutions? - Diana Bilton (UK) 
  ECFS: Your Society: Review of the year and plans for next - Stuart Elborn (UK) 
12:30-13:00  Closing Ceremony 

The conference programme is subject to change.